Experienced in Progressive Supranuclear Palsy Atypical

Mathieu Ceccaldi

Marseille, FR 
Experienced in Progressive Supranuclear Palsy Atypical
Marseille, FR 
OverviewLocationsClinical Research

Overview

Mathieu Ceccaldi practices in Marseille, France. Mr. Ceccaldi is rated as an Experienced expert by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. His top areas of expertise are Dementia, Alzheimer's Disease, Memory Loss, and Developmental Dysphasia Familial.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Progressive Supranuclear Palsy Atypical.

Gender
Male

Locations

Marseille, France
Other Locations
Bordeaux, France
Neuilly-sur-seine, 92200, France
Aix-en-provence, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Enrollment Status: Completed
Publish Date: February 17, 2025
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Drug
Study Drugs: Flutemetamol, Florbetapir
Study Phase: Phase 3
MEMENTO-VAScular COmponents of Dementia
MEMENTO-VAScular COmponents of Dementia
Enrollment Status: Completed
Publish Date: January 28, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

68 Total Publications

Faster decline of very prodromal dementia with Lewy bodies when amyloid positive.
Faster decline of very prodromal dementia with Lewy bodies when amyloid positive.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: February 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ceccaldi's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile